Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Genelux CorporationNASDAQ: GNLX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $18.54M rose 93.8% year over year, ahead of the -49.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 6616.7% from the prior quarter.
Context
- Financing cash flow amounted to 123687.5% of revenue in FY2025, down 232637.5 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +93.8% holds above the trailing-twelve-month pace of -49.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 9.9M USD
- Year-over-year change
- -65.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.9M | -65.3% |
| FY2024 | 2024-12-31 | 28.51M | -35.2% |
| FY2023 | 2023-12-31 | 44.02M | +9309.2% |
| FY2022 | 2022-12-31 | (478K) | -77.0% |
| FY2021 | 2021-12-31 | (270K) | — |
Financing Cash Flow vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -49.5% is the 6th highest of 9, against a peer median of -2.7%.
- Financing cash flow amounts to 235825.0% of revenue for GNLX, versus a peer median of 25.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $219.24M USD | +164739.1% | +946.8% | — |
| LTM Mar 2026 | $151.78M USD | +62.0% | +41.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $112.79M USD | +3.6% | — | — |
| LTM Mar 2026 | $102.13M USD | +7755.9% | +68.0% | 329441.9% | |
| LTM Dec 2025 | $45.77M USD | — | -22.1% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $18.87M USD | -49.5% | — | 235825.0% |
| LTM Mar 2026 | $17.39M USD | -123.8% | — | 25.5% | |
| LTM Dec 2025 | CHF 1.02M CHF | -9.0% | -10.2% | 28.5% | |
| LTM Mar 2026 | $191.89K USD | -76.4% | -2.7% | — | |
| LTM Mar 2026 | $95.27K USD | -100.2% | +17.8% | 19.1% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
| Peer median (excluding GNLX) | — | -2.7% | +7.5% | 25.5% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.